chidamide and Colonic-Neoplasms

chidamide has been researched along with Colonic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for chidamide and Colonic-Neoplasms

ArticleYear
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    BMC cancer, 2021, Aug-30, Volume: 21, Issue:1

    Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable response to ICIs. HBI-8000 is a novel, orally bioavailable class I selective histone deacetylase inhibitor that directly modifies antitumor activity by inducing apoptosis, cell cycle arrest, and resensitization to apoptotic stimuli in adult T cell lymphoma patients. We hypothesized that HBI-8000 functions as an epigenetic immunomodulator to reprogram the tumor microenvironment from immunologically cold (nonresponsive) to hot (responsive).. Mice bearing syngeneic tumors (MC38 and CT26 murine colon carcinoma and A20 B-cell lymphoma were treated daily with HBI-8000 (orally), alone or in combination with PD-1, PD-1ā€‰L, or CTLA-4 antibodies. MC38 tumors were also analyzed in nanoString gene expression analysis.. HBI-8000 augmented the activity of ICI antibodies targeting either PD-1, PD-L1 or CTLA-4, and significantly increased tumor regression (pā€‰<ā€‰0.05) in the above models. Gene expression analysis of the treated MC38 tumors revealed significant changes in mRNA expression of immune checkpoints, with enhanced dendritic cell and antigen-presenting cell functions, and modulation of MHC class I and II molecules.. These findings suggest that HBI-8000 mediates epigenetic modifications in the tumor microenvironment, leading to improved efficacy of ICIs, and provide strong rationale for combination therapies with ICIs and HBI-8000 in the clinical setting.. As an HDACi, HBI-8000 plays an important role in priming the immune system in the tumor microenvironment. The current preclinical data further justifies testing combination of HBI-8000 and ICIs in the clinic.

    Topics: Animals; Apoptosis; Benzamides; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021